CompletedNot Applicable

Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease

France133 participantsStarted 2015-01

Plain-language summary

Aim of the study: To evaluate risk factors of endoscopic relapse after ileocolic resection in a cohort of Crohn's disease patients treated with anti-TNF agents. Methods: From 2014 to 2022, all consecutive patients who underwent ileocolic resection for Crohn's disease treated with anti-TNF agents in two referral tertiary center were prospectively collected. Considering exclusion criteria, data from 114 patients were analyzed. The cohort was separated into 2 groups according to study period. Short and long-term outcomes were compared between the two groups. Primary outcome: Endoscopic recurrence (defined as \> i2 lesions according to Rutgeerts classification) 6 months after surgery

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with histologically proven Crohn's disease * On anti-TNF alpha: infliximab, adalimumab (ECCO 2014 recommendation) * \> 18 years old patients * All patients who have undergone ileocolic resection and whose disease site is accessible to endoscopic follow-up (first or repeat procedure) Exclusion Criteria: * Minor patients under 18 years of age * Endoscopic follow-up not possible * Pregnant women * Medical treatment other than anti-TNF alpha

What they're measuring

Endoscopic recurrence rate

Timeframe: 6 months after surgery

Trial details

NCT IDNCT06299631

SponsorUniversity Hospital, Montpellier

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-06

View on ClinicalTrials.gov More Crohn's Disease trials